New self-injecting infliximab could be boon for RA patients, Celltrion

15 June 2018

There is more activity on the biosimilars front at the annual meeting of the European Congress of Rheumatology (EULAR), the leading conference in this therapy area, with positive preliminary data from South Korean firm Celltrion Healthcare (Kosdaq: 068270).

Conference attendees have also heard from Novartis’ (NOVN: VX) biosimilars wing Sandoz, with positive switching, safety and efficacy data for its anti-TNF copycats Zessly (infliximab) and Erelzi (etanercept).

Celltrion meanwhile has data for an experimental subcutaneous formulation of CT-P13, biosimilar infliximab, which show the therapy is comparable with the intravenous version in terms of efficacy and safety, when treating rheumatoid arthritis (RA) patients for thirty weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK